MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Royalty Pharma PLC (Class A)

Ouvert

SecteurSoins de santé

32.08 0.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

31.79

Max

32.12

Chiffres clés

By Trading Economics

Revenu

441M

334M

Ventes

29M

594M

P/E

Moyenne du Secteur

16.853

57.333

BPA

1.151

Rendement du dividende

2.7

Marge bénéficiaire

56.288

EBITDA

-511M

362M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+23.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.70%

2.63%

Prochains Résultats

8 mai 2025

Date du Prochain Dividende

10 juin 2025

Date du Prochain Détachement de Dividende

16 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

18B

Ouverture précédente

31.8

Clôture précédente

32.08

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Royalty Pharma PLC (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Alphabet, Intel, AppFolio

24 avr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 avr. 2025, 23:37 UTC

Actualités

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 avr. 2025, 23:36 UTC

Actualités

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 avr. 2025, 23:13 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 avr. 2025, 23:09 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 avr. 2025, 22:51 UTC

Actualités
Acquisitions, Fusions, Rachats

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 avr. 2025, 22:48 UTC

Actualités

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 avr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 avr. 2025, 22:38 UTC

Market Talk
Résultats

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 avr. 2025, 22:24 UTC

Market Talk
Résultats

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 avr. 2025, 22:23 UTC

Résultats

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 avr. 2025, 22:09 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 avr. 2025, 22:00 UTC

Market Talk
Résultats

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 avr. 2025, 21:39 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 avr. 2025, 21:23 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 avr. 2025, 21:04 UTC

Résultats

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 avr. 2025, 21:02 UTC

Résultats

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparaison

Variation de prix

Royalty Pharma PLC (Class A) prévision

Objectif de Prix

By TipRanks

23.86% hausse

Prévisions sur 12 Mois

Moyen 39.25 USD  23.86%

Haut 42 USD

Bas 33 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

31.95 / 32.19Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.